Ceftriaxone 1000 mg Tazobactam 125 mg Injection
Ceftriaxone Sodium is a third generation cephalosporin belonging to beta lactam group of antibiotics. It is a broad spectrum bactericidal parenteral cephalosporin. The bactericidal action of Ceftriaxone is believed to be due to inhibition of cell wall synthesis leading to lysis of the bacterial cell. Tazobactam Sodium, a triazolylmethyl penicillanic acid sulfone, INTRODUCTION Tazobactam Sodium, a triazolylmethyl penicillanic acid sulfone, is a new beta lactamase inhibitor with a range of activity that includes extended spectrum plasmid mediated beta lactamases. Tazobactam lacks significant antibacterial activity of its own. By rendering β– lactamase inactive, tazobactam is able to protect the activity of various β–lactam antibiotics. Tazobactam does not appear to have β–lactamase inducing properties.
The combination of ceftriaxone (3rd generation cephalosporin) and Tazobactam (Beta lactamase inhibitor) provides a solution for treatment of such bacterial infections caused by beta lactamase resistant pathogens. Tazobactam has been combined with various beta lactam antibiotics to enhance:-
1) Their antibacterial potency.
2) Overcome bacterial resistance due to beta lactamase production.
It is efective for
Lower respiratory tract infections and community-acquired pneumonia
Skin and skin structure infections
Acute bacterial otitis media
Urinary tract infections
Pelvic inflammatory disease
Bacterial septicemia
Bacterial Meningitis
Uncomplicated gonorrhea
Intra-abdominal infections
Commonly used for surgical prophylaxis – prevention of bacterial infection before and after surgery
MK Medicine is a leading pcd franchise provider, contract manufacturer and hospital supplier of WHO-GMP certified Ceftriaxone 1000 mg Tazobactam 125 mg Injection
1 Vial + W.F.I.
History of penicillin allergy; lactation. Consider possibility of pseudomembranous colitis in patients who present with diarrhoea subsequent to the admin of antibacterial agents. Monitor prothrombin time in patients with impaired vit K synthesis or low vit K stores during treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms. Caution in patients with a history of GI disease, especially colitis. Discontinue treatment in patients who develop signs/symptoms suggestive of gallbladder disease. Not to be used in hyperbilirubinemic neonates, especially prematures.
Common adverse drug reactions (ADRs) for the β-lactam antibiotics include
•Diarrhea
•Nausea
•Rash
•Urticaria
•Superinfection (including) Candidacies
•Pain and inflammation at the injection site is also common for parenterally administered β-lactam antibiotics.
Although the transient elevations of BUN and serum creatinine have been observed at the recommended dosage the nephrotoxic potential of Ceftriaxone / Tazobactam is similar to that of other cephalosporins. Ceftriaxone / Tazobactam should be prescribed with caution in individuals with a history of gastrointestinal disease especially colitis. Alterations in prothrombin times have occurred rarely in patients treated with ceftriaxone tazobactam.
Important Notice:- The Database is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Amikacin Sulphate 100 mg Injection